Pharma Focus Asia

Kesimpta® (ofatumumab), The First Self Administrated B-cell Therapy Developed

Novartis develops the first and only self administered B-cell therapy, Kesimpta®, for the treatment of relapsing Multiple sclerosis (MS).

Kesimpta® becomes the first new B-cell therapy, which can be self-administered once in a month at home by means of Sensoready® autoinjector pen. Due to its safety profile and well-tolerated behaviour patients can now use this autoinjector at home, avoiding visits to the infusion center.

Kesimpta® (ofatumumab) being an subcutaneous autoinjection can be used as the new precise dosage treatment option for Relapsing forms of multiple sclerosis (RMS)patients including  Clinically Isolated Syndrome (CIS), Relapsing-Remitting (RRMS), and active Secondary Progressive Multiple Sclerosis (SPMS).  

Kesimpta may stop the growth of new disease activity in RMS patients. The new treatment developed will lower the risk in new brain lesions, reducing relapses and slowing underlying disease progression.

Some of the side effects caused by the injection of KESIMPTA are headache, infections in the upper respiratory tract, HBV reactivation, Progressive Multifocal Leukoencephalopathy (PML) and weakened immune system.

US Food and Drug Administration (FDA) has granted the first and only self-administered, targeted B-cell therapy for patients with relapsing multiple sclerosis.

MS is an auto-immune disease affecting the central nervous system, by destructing the myelin sheath surrounding the nerve fibres of the brain, optic nerves, and spinal cord.

magazine-slider-imageCytiva - Supor Prime filtersMFA + MMA 2024CPHI China || PMEC China 2024Asia Healthcare Week 2024CPHI Korea 2024CHEMICAL INDONESIA 2024World Orphan Drug Congress Europe 2024INALAB 2024Advanced Therapies USA 2024ISPE Singapore Affiliate Conference & Exhibition 20242024 PDA Cell and Gene Pharmaceutical Products Conference 2024 PDA Aseptic Manufacturing Excellence Conference2024 PDA Aseptic Processing of Biopharmaceuticals Conference3rd World ADC Asia 2024LogiPharma Asia 2024